We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $22.2B
1-Year Est. Return 58.34%
This Fund
S&P 500
This Quarter Est. Return
+31.13%
1 Year Est. Return
+58.34%
3 Year Est. Return
+153.02%
5 Year Est. Return
+199.78%
10 Year Est. Return
+811.75%
AUM
$22.2B
AUM Growth
+$2.96B
Cap. Flow
-$534M
Cap. Flow %
-2.4%
Top 10 Hldgs %
32.73%
Holding
727
New
37
Increased
291
Reduced
287
Closed
50

Top Buys

Rank Stock Value
1
AVGO icon
Broadcom
AVGO
+$110M
2
ENTG icon
Entegris
ENTG
+$53.1M
3
HLT icon
Hilton Worldwide
HLT
+$45.7M
4
ISRG icon
Intuitive Surgical
ISRG
+$44.3M
5
WDC icon
Western Digital
WDC
+$41.5M

Top Sells

Rank Stock Value
1
MU icon
Micron Technology
MU
+$68.2M
2
JNJ icon
Johnson & Johnson
JNJ
+$67.3M
3
MSFT icon
Microsoft
MSFT
+$64.1M
4
GILD icon
Gilead Sciences
GILD
+$63.1M
5
ON icon
ON Semiconductor
ON
+$62.5M

Sector Composition

Rank Sector Weight
1 Technology 38.31%
2 Healthcare 24.36%
3 Financials 9.42%
4 Communication Services 7.08%
5 Consumer Discretionary 6.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DNLI icon
151
Denali Therapeutics
DNLI
$3.56B
$30.6M 0.14%
1,189,886
+90,041
+8% +$1.85M
ADBE icon
152
Adobe
ADBE
$106B
$30.3M 0.14%
148,071
+26,224
+22% +$6.21M
CMI icon
153
Cummins
CMI
$77.2B
$29.9M 0.13%
42,024
+28,141
+203% +$18.5M
FTNT icon
154
Fortinet
FTNT
$115B
$29.4M 0.13%
191,608
-137,367
-42% -$15.9M
TXN icon
155
Texas Instruments
TXN
$236B
$29.1M 0.13%
97,590
+223
+0.2% +$61.9K
UTHR icon
156
United Therapeutics
UTHR
$20.9B
$29.1M 0.13%
53,684
-9,382
-15% -$5.28M
DFTX
157
Definium Therapeutics
DFTX
$5.12B
$28.9M 0.13%
614,425
-679,204
-53% -$16.8M
MTD icon
158
Mettler-Toledo International
MTD
$27B
$28.1M 0.13%
22,037
+579
+3% +$698K
RNR icon
159
RenaissanceRe
RNR
$13.7B
$28.1M 0.13%
88,691
+67,824
+325% +$20.4M
XENE icon
160
Xenon Pharmaceuticals
XENE
$5.79B
$27.9M 0.13%
462,768
-13,726
-3% -$762K
PTC icon
161
PTC
PTC
$15.3B
$27.7M 0.12%
243,668
+8,503
+4% +$1.15M
TPR icon
162
Tapestry
TPR
$24.4B
$27M 0.12%
184,964
+12,108
+7% +$1.73M
IQV icon
163
IQVIA
IQV
$44.1B
$26.9M 0.12%
139,445
-87,349
-39% -$15.2M
PGR icon
164
Progressive
PGR
$127B
$26.7M 0.12%
122,421
-7,778
-6% -$1.57M
TVTX icon
165
Travere Therapeutics
TVTX
$6.15B
$26.7M 0.12%
470,265
+100,270
+27% +$4.45M
BBAR icon
166
BBVA Argentina
BBAR
$3.03B
$26.2M 0.12%
+1,335,000
New +$22.5M
DGX icon
167
Quest Diagnostics
DGX
$26.2B
$25.5M 0.11%
120,238
+16,102
+15% +$3.16M
MCO icon
168
Moody's
MCO
$85.5B
$25.3M 0.11%
55,960
+286
+0.5% +$128K
BCRX icon
169
BioCryst Pharmaceuticals
BCRX
$2.55B
$25.1M 0.11%
2,514,949
+228,108
+10% +$2.06M
CHD icon
170
Church & Dwight Co
CHD
$23.4B
$25.1M 0.11%
259,129
+145,660
+128% +$13.9M
EL icon
171
Estee Lauder
EL
$37.6B
$25M 0.11%
316,449
+15,417
+5% +$1.25M
ARQT icon
172
Arcutis Biotherapeutics
ARQT
$3B
$24.9M 0.11%
949,839
-136,812
-13% -$3.19M
IBM icon
173
IBM
IBM
$221B
$24.8M 0.11%
88,387
-6,944
-7% -$1.75M
BRKR icon
174
Bruker
BRKR
$8.91B
$24.8M 0.11%
411,700
-264,724
-39% -$12.4M
VLTO icon
175
Veralto
VLTO
$23.5B
$24.6M 0.11%
277,593
+50,789
+22% +$4.41M
5 6
7
8 9

Similar funds

DCP
Darsana Capital Partners New York $22.3B AUM 42.01% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return
TAF
Tredje AP-fonden Se-111 91 Stockholm, Sweden $22.1B AUM 41.68% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $22.1B AUM 45.54% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $22.3B AUM 36.19% 1-Year Est. Return
CIG
Capricorn Investment Group Palo Alto, California $22.5B AUM 50.37% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Candriam SCA's Q2 2026 Portfolio in Review

As of Q2 2026, Candriam SCA held 727 positions worth $22.2B, up 15% from $19.3B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Candriam SCA's Q2 2026 filing shows 37 new, 291 increased, 287 reduced and 50 closed positions. Its largest new stake was BBVA Argentina: 1,335,000 shares worth $26.2M. The largest sale was Micron Technology, an estimated $68.2M.

By sector, the portfolio is most concentrated in Technology at 38% of assets, up from 33% a quarter earlier, followed by Healthcare and Financials.

  • Candriam SCA's largest Q2 2026 buy was BBVA Argentina: 1,335,000 shares worth $26.2M.
  • Candriam SCA added most to Broadcom in Q2 2026, an estimated $110M increase.
  • Candriam SCA's biggest Q2 2026 reduction was Micron Technology, cutting an estimated $68.2M.
  • Candriam SCA fully exited Ascendis Pharma A/S in Q2 2026, selling an estimated $52.7M.
  • Candriam SCA's ten largest holdings make up 33% of its $22.2B portfolio in Q2 2026.
  • Candriam SCA opened 37 new positions and closed 50 in Q2 2026.
  • Candriam SCA's portfolio value rose 15% quarter-over-quarter to $22.2B.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.